ABSTRACT G protein-coupled receptors (GPCRs) play central roles in most physiological functions, and mutations in them cause heritable diseases. Whereas crystal structures provide details about the structure of GPCRs, there is little information that identifies structural features that permit receptors to pass the cellular quality control system or are involved in transition from the ground state to the ligand-activated state. The gonadotropinreleasing hormone receptor (GnRHR), because of its small size among GPCRs, is amenable to molecular biological approaches and to computer modeling. These techniques and interspecies comparisons are used to identify structural features that are important for both intracellular trafficking and GnRHR activation yet distinguish between these processes. 
Introduction
The hypothalamic decapeptide, gonadotropin-releasing hormone (GnRH), binds a cognate G protein-coupled receptor (GPCR) in the pituitary gonadotrope. This event stimulates the synthesis and release of the gonadotropins (luteinizing hormone and follicle-stimulating hormone). Mammalian GnRHRs appear unique among GPCRs because of the absence of an intracellular carboxyl-terminal domain involved in receptor trafficking, desensitization, and arrestin-mediated internalization of other GPCRs (Lefkowitz, 1998) . Primate GnRHRs, unlike their rat and mouse orthologs, are poorly trafficked from the endoplasmic reticulum (ER) to the plasma membrane (PM) . Approximately half of the newly synthesized receptor molecules are misfolded and retained in the ER (Leañ os-Miranda et al., 2002; Conn et al., 2006a; Conn and Janovick, 2009b) . This distribution of human GnRHR (hGnRHR) between the ER and PM is highly sensitive to point mutations (Knollman et al., 2005) whose effects on receptor trafficking are the underlying cause of certain forms of disease (Leañ os-Miranda et al., 2002 Janovick et al., 2006) . We found that misfolded and misrouted hGnRHR mutants can be rescued by target-spe-cific pharmacoperones, small cell-permeating molecules that serve as folding templates that enable them to pass the cellular quality control system (QCS) Conn and Janovick, 2009a,b) . The small size of the hGnRHR has made it possible to construct hundreds of mutants that have been useful in understanding structures that are important for trafficking to the PM.
Prior studies suggested that the disulfide bridge between Cys 114 and Cys 196 , orthologs of which are common among GPCRs, is an absolute requirement for trafficking of the hGnRHR to the PM (Janovick et al., 2006) . Mutants in which either end of the disulfide bridge is converted to Ala are retained in the ER by the QCS and cannot be rescued with pharmacoperones . Misfolding and misrouting of WT receptor are also caused by failure of formation of the second disulfide bridge between Cys 14 and Cys 200 (Janovick et al., 2006) , but pharmacoperones rescue them by allowing passage through the QCS. When the pharmacoperone is removed, cells expressing hGnRHR [C14A or C200A] regain the ability to bind and respond to agonists, suggesting that, although this structure is important for trafficking, it is not absolutely required for receptor activation by agonist.
Formation of the Cys 14 -Cys 200 bridge is destabilized by residue Lys 191 in primates (or Glu 191 in many other mammals) (Janovick et al., 2006) ; in the rat and mouse sequence, there is no orthologous residue, making these receptors one residue shorter than the human sequence (Knollman et al., 2005; Janovick et al., 2006) . Rodent GnRHRs traffic to the plasma membrane with much higher efficiency than does the human counterpart. Deletion of the Lys 191 residue also rescues the hGnRHR [C14A or C200A] 191 alone in the rat sequence is without substantial effect on trafficking to the plasma membrane (Knollman et al., 2005; Janovick et al., 2006) .
A salt bridge connecting Glu 90 -Lys 121 also seems to be required for trafficking. Disruption of this ion pair in the E90K mutant is the underlying cause in some cases of human hypogonadotropic hypogonadism (Janovick et al., 2009) . When rescued by pharmacoperones [which form a surrogate bridge (Janovick et al., 2009)] or by deletion of residue Lys 191 , this mutant reveals constitutive activity (CA) (Janovick and Conn, 2010) , presenting the first reported mutant with CA and the first structural link relating the common requirements for trafficking and receptor activation. The salt bridge that is required to be intact for trafficking results in receptor activation when it is broken; thus, ER retention of this mutant protects the cell from unregulated CA.
We have used this information to construct a model for the receptor, aided by recent advances in the structure of both the inactive rhodopsin and photoactivated opsin in a complex with a G protein fragment (Topiol and Sabio, 2009 ). In the present study, we provide evidence from computer modeling and site-directed mutagenesis for the existence of a second salt bridge, Arg 38 -Asp 98 , and suggest structural features of the inactive and active receptor conformations that explain the observation that Asp 2 -GnRH, which is inactive with the WT receptor (neither agonist nor antagonist), becomes an agonist with rescued E90K.
Materials and Methods
Modeling of Human GnRH Receptors. The homology models of human GnRH receptor (UniProt number P30968-1, residues 1-328) in the inactive and active states were developed using crystal structures of bovine rhodopsin in the dark-adapted state (Protein Data Bank code 1U19) and, after photoactivation, cocrystallized with the G protein-derived peptide (Protein Data Bank code 3DQB), respectively. The models were generated as described previously for melanocortin receptors Pogozheva et al., 2005) . The procedure included the following steps: 1) generation of initial models; 2) loop modeling; 3) ligand docking using experimental restraints; 4) iterative distance geometry refinement of ligand-receptor complexes; 5) energy minimization; and 6) model validation.
Initial precomputed models that were obtained from the Protein Modeling Portal (http://www.proteinmodelportal.org/) showed some misalignments, defects in helices and loops, and lack of correct disulfides. We corrected these problems in the second step of the modeling procedure by combining structural elements from different GPCR templates and using alternative sequence alignments. We modeled the intracellular loop IL3 as extensions of TM5 and TM6 with a short interhelical connection, in accordance with the squid rhodopsin template (Protein Data Bank code 2Z73). Conformations of the N terminus, intracellular loop IL1, and the extracellular loop EL3 were modeled using the rhodopsin structure with the corrected sequence alignments. The long EL2 (residues 181-204) was modeled based on several GPCR templates (Protein Data Bank codes 3EML, 1U19, and 2Z73) to provide the formation of both disulfides while leaving space for docking the decapeptide ligands.
In the third step, an NMR-derived II'␤-turn conformation of GnRH, pGlu 1 -His 2 -Trp 3 -Ser 4 -Tyr 5 -Gly 6 -Leu 7 -Arg 8 -Pro 9 -Gly 10 -NH 2 (Protein Data Bank code 1YY1), was selected for the docking experiment, as this conformation is consistent with 1 to 5 and 4 to 10 cyclization in bicyclic ligands with sub-nanomolar affinity . This conformation of GnRH was manually docked in the active conformation of the receptor to comply with experimentally identified contacts between GnRH analogs and receptor residues: pGlu 1 (Sealfon et al., 1997; Flanagan et al., 2000; Hoffmann et al., 2000; Hövelmann et al., 2002; Coetsee et al., 2008; Millar et al., 2008; Stewart et al., 2008) . A similar mode of GnRH docking has been proposed and experimentally validated . The same ligand-receptor contacts were used for docking of Asp 2 -GnRH in the inactive receptor conformation. The ligand-receptor complexes were refined by distance geometry calculations ( Gü ntert and Wü thrich, 1991) with template-derived and experimental structural restraints. The distance-geometry refinement was employed to remove steric overlaps and to maximize the number of H-bonds in the receptor and between the receptor and ligand. In this step, H-bonds that can be formed between polar residues of ligand and receptor were added as distance constraints. In particular, H-bonding interactions with pyroglutamic acid of GnRH involved residues from TM4 (Gln174) and TM6 (Tyr283). Different positions of EL2 were generated with and without docked peptide. Several residues with correlated behavior in multiple sequence alignments were brought into contact during several iterations of the refinement procedure. Models that better satisfied structural restraints and maximized the number of intra-and intermolecular H-bonds were used for the subsequent energy minimization. Energy minimization of ligand-receptor complexes was then performed using the CHARMm potentials (QUANTA; Accelrys, San Diego, CA), with a dielectric constant of ε ϭ 10 and the adopted basis Newton-Raphson minimization method (100 iterations).
To further test the models for their compliance with known experimental data, we docked agonist, buserelin [pGlu Mutant Receptors. WT and mutant GnRHR cDNAs for transfection were prepared as reported previously ; the purity and identity of plasmid DNAs were verified by dye terminator cycle sequencing (Applied Biosystems, Foster City, CA). Pharmacoperones In3, Q89, and Q103 (Merck and Company, Boston, MA) were obtained as indicated (Conn and Janovick, 2009a; Janovick et al., 2009) . Full chemical structures and the mechanism of action on the hGnRHR have been reported previously (Conn and Janovick, 2009a,b; Janovick et al., 2009) .
Transient Transfection. COS-7 cells were cultured in growth medium (DMEM, 10% fetal calf serum, and 20 g/ml gentamicin) at 37°C in a 5% CO 2 humidified atmosphere. For transfection of WT or mutant receptors into cells, 5 ϫ 10 4 cells were plated in 0.25 ml of growth medium in 48-well Costar cell culture plates (Corning Life Sciences, Lowell, MA). Twenty-four hours after plating, the cells were washed with 0.5 ml of Opti-MEM and then transfected with WT or mutant receptor DNA with pcDNA3.1 (empty vector) to keep the total DNA constant (100 ng/well). Lipofectamine was used according to the manufacturer's instructions. Five hours after transfection, 0.125 ml of DMEM with 20% fetal calf serum and 20 g/ml gentamicin was added. Twenty-three hours after transfection, the medium was replaced with 0.25 ml of fresh growth medium. Where indicated, pharmacoperones (indicated concentration) in 1% dimethyl sulfoxide ("vehicle") were added for 4 h in respective media to the cells and then removed 18 h before agonist treatment (Leañ os-Miranda et al., 2003b) . In the present study, we used trypan blue exclusion to confirm cell viability after drug exposure.
Inositol Phosphate Assays. Twenty-seven hours after transfection, cells were washed twice with 0.5 ml of DMEM/0.1% BSA/20 g/ml gentamicin, "preloaded" for 18 h with 0.25 ml of 4 Ci/ml myo- [2- 3 H(N)]inositol in inositol-free DMEM, and then washed twice with 0.3 ml of DMEM (inositol-free) containing 5 mM LiCl and treated for 2 h with 0.25 ml of a saturating concentration of buserelin (10 Ϫ7 M) in the same medium. When constitutive activity was assessed, buserelin was omitted from the assessment period. Total inositol phosphate (IP) was then determined (Janovick et al., 2006) . This assay has been validated as a sensitive measure of PM expression for functional receptors when expressed at low amounts of DNA (Ͻ100 ng/125 l) and stimulated by excess agonist (Cook and Eidne, 1997; Leañ os-Miranda et al., 2002 Janovick et al., 2003a,b; Ulloa-Aguirre et al., 2004; Castro-Fernandez et al., 2005; Knollman et al., 2005; Conn et al., 2006a Conn et al., ,b, 2007 Conn and Janovick, 2009a,b) .
Binding Assays. Cells were cultured and plated in growth medium as described above, with the exception of 10 5 cells in 0.5 ml of growth medium, and added to 24-well Costar cell culture plates (cell transfection and medium volumes were doubled accordingly). Twentythree hours after transfection, the medium was replaced with 0.5 ml of fresh growth medium with or without pharmacoperone (1 g/ml In3). Twenty-seven hours after transfection, cells were washed twice with 0.5 ml of DMEM containing 0.1% BSA and 20 g/ml gentamicin, and then 0.5 ml of DMEM was added. After 18 h, cells were washed twice with 0.5 ml of DMEM/0.1% BSA/10 mM HEPES, and then 2 ϫ 10 6 cpm/ml 125 I-buserelin, prepared in our laboratory (specific activity, 700 -800 Ci/g), was added to the cells in 0.5 ml of the same medium and allowed to incubate at room temperature for 90 min, consonant with maximal binding (Brothers et al., 2002) . New receptor synthesis during this period is negligible at room temperature. After 90 min, the media were removed, and radioactivity was measured (Brothers et al., 2003) . To determine nonspecific binding, the same concentrations of radioligand were added to similarly transfected cells in the presence of 10 g/ml unlabeled GnRH. Statistics. Data (n Ն 3) were analyzed with one-way analysis of variance and then the Holm-Sidak test paired with the Student's t test (SigmaStat 3.1; SPSS Inc., Chicago, IL). Means Ϯ S.E.M. are shown.
Results
Two Salt Bridges and Two Cys Bridges Are Predicted in the hGnRHR. Homology models of hGnRH receptors in the active and inactive states in complexes with GnRH (or GnRH-II or buserelin) and Asp 2 -GnRH (or cetrorelix), respectively, were developed by distance geometry calculation using structural restraints from rhodopsin templates (Protein Data Bank codes 3DQB and 1U19), NMR structure of GnRH (Protein Data Bank code 1YY1), and experimentally determined ligand-receptor contact points (see Materials and Methods). The transmembrane regions of the models closely resemble those in rhodopsin structures, with a root mean square deviation of 1.31 and 1.84 Å (for 219 C␣ atoms) between human GnRH receptor and bovine rhodopsin in inactive and active conformations, respectively. The largest difference is in the position of EL2, which, in the GnRH receptor, is outwardly displaced relative to its position in rhodopsin, exposing the large binding cavity for decapeptide ligands.
In our model, two experimentally identified disulfide bridges that connect EL2 with the N terminus (Cys 14 -Cys 200 ) and TM3 (Cys 114 -Cys 196 ) respectively, are present ( Fig. 1 ). We also observed two interhelical ion pairs between TM1 and TM2 (Arg 38 -Asp 98 ) and between TM2 and TM3 (Glu 90 -Lys 121 ). The first ion pair is conserved in the majority of GnRH receptors, whereas the second one is specific for mammalian receptors. Based on the model, we hypothesized that correct translocon-assisted folding and association of helices require timely formation of ionic pairs between TM1-TM2 and TM2-TM3 and consequential closure of two disulfide bridges that stabilize the receptor structure enabling its traffic to the plasma membrane.
During the refinement procedure, we tested several conformations of the large EL2 to understand the molecular mechanisms underlying the observed importance of Lys 191 , Cys 14 -Cys 200 disulfide bridge, and noncontiguous four-residue motif for receptor trafficking and activation. We found that, in the WT receptor, the presence of charged Lys 191 in the middle of EL2 does not permit the insertion of the loop between helices, because burial of the highly polar Lys 191 side chains is energetically unfavorable and creates steric clashes with the N terminus (Fig. 1B) . On the other hand, deletion of the Lys 191 residue from the human receptor allows a 7-Å inward shift of the middle part of EL2 (at Gln 195 ) toward the ligand binding pocket (Fig. 1C) ) in homology model of human GnRH receptor in the inactive conformation. Inactive (gray) and active (yellow) states were modeled using rhodopsin crystal structures (Protein Data Bank codes 1U19 and 3DQB, respectively). EL2 loops (residues 181-204) are colored blue, Cys residues are colored orange, Arg and Lys residues are colored blue, and Asp and Glu residues are colored red. Superposition of active and inactive conformation shows that the largest conformational changes include outward rigid body movement of TM6, movement of TM5 toward TM6, tilting of TM7, and shift of its middle part toward TM2. B and C, the proposed movement of the EL2 in the wild-type and mutant human GnRH receptor. B, homology models of the wild-type human receptor (yellow) in active state with GnRH decapeptide (purple) show the upper position of the EL2 (blue), which is attached to the receptor by two disulfide bridges (Cys GnRH receptor may also be stabilized by the H-bonding network formed between residues from TM1 (Asn 53 ), TM2 (Asn 87 ), and TM7 (Asp 319 ), which are conserved in rhodopsinlike GPCRs. The structural and functional importance of these residues for trafficking, activation, and coupling pathways of GnRH receptors has been established (Flanagan et al., 1999 (Fig. 1, D-F (Fig. 1D) . The Glu 90 -Lys 121 pair connecting TM2 and TM3 may also participate in this network via tightly bound water molecules, which have been observed in GPCR crystal structures (Angel et al., 2009 . When rescued by either of these means, this mutant showed CA, i.e., the increase of agonistindependent IP production (Janovick and Conn, 2010) . Accordingly, we examined mutations at the Lys 121 end of this salt bridge to determine whether that perturbation also resulted in CA. Mutation of Lys 121 to Ala did not produce significant CA either alone or following rescue by pharmacoperones In3 or Q103 (Fig. 2) . The additional deletion of Lys 191 resulted in modest CA of human K121A-desLys 191 , particularly when it was combined with pharmacoperone rescue of the double mutant. In this group, agonist-independent IP production increased by 17 to 42% above basal. Mutants K121R or K121R-desLys 191 did not show CA with or without rescue with either pharmacoperone (data not shown).
We previously examined the IP production by activation of Lys 121 mutants with the GnRH receptor agonist buserelin (Janovick et al., 2009) . Among those single mutants at residue 121 (Ala, Asp, Glu, Gly, Asn, Gln, or Arg), only the conservative substitution, K121R, led to a response to buserelin that was comparable to that of the WT hGnRHR (without pharmacoperone rescue). There was a slight responsiveness of K121A and K121Q and a more modest response of K121G and K121N to buserelin when these mutants were first rescued by pharmacoperone In3. There was virtually no response when Lys 121 was converted to the negatively charged Asp or Glu. Further deletion of Lys 191 in these mutants resulted in responsiveness from K121R, a more modest response from K121Q Ͼ Ala Ͼ Asn Ͼ Gly and no response from the negatively charged Asp or Glu.
Comparing the results for agonist-stimulated receptor activation and constitutive activation suggests that mutants in position 121, which, when rescued, result in CA, are not necessarily those that show the best response to agonist. Part of this uncoupling may reflect the observation that Lys 121 is a potential binding site for agonists of GnRH.
These data are consistent with our modeling of K121A and K121R mutants, which suggests that modest CA observed in the K121A, but not in the K121R mutant, may be related to breaking of the ionic bridge in the K121A mutant. However, the lower CA of K121A in comparison with the E90K mutant can be explained by the lack of additional stabilization of the TM2-TM7 proximity, which in the E90K mutant may be reinforced by Lys 90 -Asp 319 ionic interactions. On the other hand, Arg 121 , but not Ala 121 , would interact with the ligand similar to Lys 121 . This may explain the better response to buserelin of the K121R mutant relative to the K121A mutant. . COS-7 cells were transfected with 100 ng of WT or mutant cDNA as described under Materials and Methods. Mutants were incubated in media alone or rescued with pharmacoperone (In3, Q103); pharmacoperones In3 and Q103 were washed out, and IP production was measured in response to media alone (no agonist). The dashed horizontal line shows basal level of vector only. Means Ϯ S.E.M.s are shown for three independent experiments, each performed in replicates of four. Restoration of responsiveness of R38A and R38K by In3 suggests that they are misrouted (probably ER-retained mutants) and rescuable, whereas R38D and R38E may be permanently retained or unable to bind agonist or achieve the active configuration needed to interact with G proteins. The ability of pharmacoperones to rescue a substantial amount of the responsiveness of R38A, Lys, and Ser, but not the mutants with charge changes, is reminiscent of the pattern seen with mutants that do not pass the cellular QCS (Conn et al., 2006b) .
To better understand the functional role of charged residues Arg 38 and Asp 98 , we assessed the dose-response curves in the R38S, Ala, and Lys and D98E, Gly, and Asn mutants (Fig. 4) with buserelin. It seems that relative affinity to buserelin is significantly (Ͼ50-fold) decreased for all of these mutants. This contrasts with the unchanged affinity of the E90K mutant to buserelin. These results indicate that, unlike Glu 90 , both Arg 38 and Asp 98 are involved in key proteinligand interactions. Therefore, their substitutions not only destabilize the receptor but also impair agonist binding and/or activation properties of the receptor. This is consistent with our receptor models (Fig. 1, D-E (Fig. 5) . In contrast, the E90K mutants of 
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at ASPET Journals on July 13, 2017 jpet.aspetjournals.org human and mouse GnRHRs, but not rat GnRHR, show measurable CA after In3 rescue (Fig. 5) . We have attributed the appearance of CA to alteration of the relation between TM2 and TM3 in a fashion that may be similar to the events that occur after the binding of the natural ligand (Janovick and Conn, 2010) . CA is the most prominent for the human mutant and modest for the rat and mouse mutants. This difference in the ability to rescue is not likely to be attributed to the superior recognition of In3 by the human sequence, because this molecule retains good affinity (1.7 nM) to the rat GnRHR (Chu et al., 2001) .
These mutagenesis results indicate that differences in CA between species may be related to the different conformational flexibility of receptors. The computational modeling suggests that, in rodent receptors, EL2 may be deeply inserted between helices, whereas in the human receptor, this loop is more polar and probably is shifted from the protein milieu to the water environment. The increased stability of rat and mouse receptor attributed to EL2 interactions with helices may prevent manifestation of receptor activation in the absence of the agonist.
Requirement of the Cys 14 -Cys 200 Disulfide Bridge for Constitutive and Agonist-Induced Receptor Activation. Different levels of CA among the three species examined led us to consider those physical differences known to exist between them as a possible explanation for this difference. Rat WT GnRHR does not require the formation of Cys 14 -Cys 200 for trafficking as does the human GnRHR (Janovick et al., 2006) . The mouse is intermediate in the requirement for this bridge. These data indicate the apparent structural flexibility of a human receptor, which demands an additional stabilization by the second disulfide.
To investigate the connection between the receptor ability to undergo conformational transitions and structural constraints in EL2, we measured responsiveness to agonist of WT and E90K mutants of human (Fig. 6A) , rat (Fig. 6B) , and mouse (Fig. 6C) sequences after rescue by pharmacoperone In3 and/or deletion of residue Lys 191 . This was compared with mutants also containing C14A and C200A modifications that preclude formation of the Cys 14 -Cys 200 bridge. The human, mouse, and rat E90K sequences show measurable CA after rescue by In3. CA is substantially inhibited by the introduction of mutations C14A or C200A, even though the disulfide bridge is not a requisite for trafficking to the plasma membrane in the rat sequence (Fig. 5) (Janovick et al., 2006) . These observations suggest that the Cys bridge is required for CA in all species of E90K mutants examined. Lys 191 deletion provides measurable improvement in CA of In3-rescued E90K human receptor mutants. This improvement is highly pronounced for the E90K-⌬Lys 191 mutant having both disulfide bridges (up to 10-fold increase in IP production; Fig, 5A ), and it is noticeable even for receptors with a broken Cys 14 -Cys 200 bridge. The effect of Lys 191 deletion is possibly attributed to improved receptor trafficking.
The elimination of the Cys 14 -Cys 200 disulfide bridge similarly affects agonist-induced activation of E90K mutants of human and rodent receptors (Fig. 6 ). This effect is larger for human and mouse receptors but also significant (up to 4-fold decrease of IP production) for the rat receptor of which trafficking is less dependent of this disulfide (Knollman et al., 2005) . All double mutants cannot be fully rescued by the In3 pretreatment. Deletion of Lys 191 in human receptor in combination with In3 additionally improves IP production but does not reproduce the function of the WT receptor. A similar experiment cannot be done for the mouse or rat sequence because this residue is not normally present in the natural sequence. These results indicate that the presence of the Cys 14 -Cys 200 disulfide supports ligand-induced activation of receptors from different species.
The receptor model suggests that receptor activation may involve movements of TM2, TM3, TM6, and TM7 together with EL2, which opens the ligand binding pocket for agonist. The Cys 14 -Cys 200 disulfide bridge that restrains the position of EL2 relative to surrounding helices may be critical to provide proper conformational changes associated with constitutive or agonist-induced receptor activation.
In other experiments, we assessed the impact of breaking the disulfide bridge in the human WT and E90K mutants on the receptor trafficking monitored by the specific binding of radioligand (Fig. 7) . These data show that mutant E90K is , and mouse (C) GnRHR. COS-7 cells were transiently transfected with 100 ng of cDNA as described under Materials and Methods. Mutants were incubated in media alone or after rescue with pharmacoperone In3 as described under Materials and Methods; In3 was then washed out, and IP production was measured in response to media alone (no agonist added). The dashed horizontal line shows basal level of vector only. Means Ϯ S.E.M.s are shown for three independent experiments, each performed in replicates of four. not present at the plasma membrane, consistent with the previous observation that this mutant is retained in the ER by the cellular quality control system . The amount of functional receptor in the plasma membrane increased after pretreatment by In3. E90K mutants that cannot form the Cys 14 -Cys 200 bridge were further impaired in trafficking. This effect was partially reversed by the deletion of Lys
191 . These data demonstrate that, while considering the role of the Cys 14 -Cys 200 bridge in receptor activation, it is important to consider its effect on receptor trafficking. Thus, the small effect of Lys 191 deletion on the constitutive and agonist-induced activity of the E90K mutant may be fully attributed to the improved trafficking of this receptor.
Impact of EL2 Interactions on Ligand Binding and Constitutive Activation of E90K Mutant. We also examined the impact of replacing the noncontiguous four-residue motif that allows Lys 191 to inhibit trafficking (Janovick et al., 2006) . When the human motif in hGnRHR[E90K] was replaced with the orthologous rat residues (i.e., L112F, Q208E, L300V, and D302E), this decreased the measured CA but modestly increased the IP production after rescue. The same was true when Lys 191 was deleted from this sequence (Fig. 8) . It is presumed that this is the result of increased trafficking of these mutants to the plasma membrane. It is noteworthy that the human E90K mutant with rat-like substitutions, including the deletion of Lys 191 , which demonstrates the biggest CA, has decreased CA after pretreatment by In3. This effect may be attributed to the incomplete removal of the drug, which may inhibit CA of the receptor. Another interpretation may be related to the possibility that folding and stability of the human receptor with rat-like substitutions are more effective in the absence of drug, which may compete with the EL2 for the space in the ligand binding pocket.
To further explore the structural role of EL2 in human and rat receptors, we assessed the ability of pharmacoperone Q89 to inhibit interactions with agonist of rat and human receptor mutants in which Lys 191 was deleted in hGnRHR together with other rat-like replacements in the noncontiguous motif and vice versa. We observed that Q89 binds human receptor with Ͼ100-fold higher binding affinity than rat receptor (Fig. 9) . We also found that the binding of Q89 to the human receptor (Fig. 9A) was inhibited by Lys 191 deletion. ) cDNA (with 75 ng of empty vector) and rescued with or without pharmacoperone In3, as described under Materials and Methods for binding studies. The In3 was then washed out, and specific binding was determined by using 2 ϫ 10 6 cpm/ml 125 I-buserelin for 90 min at room temperature. The tracer was removed, cells were washed twice, and radioactivity was measured. Means Ϯ S.E.M.s for total binding averaged 7%.
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Consecutive substitution of the human receptor motif by four rat residues decreased the binding affinity to Q89, resulting in the low rat-like affinity. In contrast, rat GnRHR (Fig. 9B ) after substitution with human residues at positions 112, 207 (corresponding to 208 in the human sequence), 299 (300 in the human sequence), and 301 (302 in the human sequence) showed significantly improved Q89 binding, reaching a binding affinity near that for the human sequence. However, the addition of Lys 191 in the rat sequence did not demonstrate any additional effect.
These data are consistent with our suggestion regarding the possible obstruction of the ligand binding pocket of rat receptor by EL2 deeply inserted between helices. Blocking the access to the binding pocket would prevent binding of pharmacoperone Q89. On the other hand, steric interference from Lys 191 in the human receptor would prevent the insertion of EL2 in the ligand binding pocket. The high accessibility of the binding pocket probably explains the high binding affinity of hGnRHR for Q89. The lack of effect of Lys 191 insertion in the rat receptor on the Q89 binding may be attributed to smaller steric hindrances of this residue with the surrounding receptor helices and loops.
To (Knollman et al., 2005) . In Fig. 8 , we show that the S217G mutation reduces CA in the human E90K mutant, suggesting a role for this residue in the active state of the receptor. This effect cannot be fully reversed either by In3 or by the Lys 191 deletion (Fig. 8) , suggesting that the loss of the ability to produce CA is not likely due to ER retention. In our model of the active conformation (Fig. 1, E and F To further explore this possibility and the role of the Ser 217 -Tyr 284 H-bond, we prepared Y284F and Y284C mutants that cannot form this H-bond. The Y284C mutant also lacks the aromatic moiety of the native residue. Agonist buserelin-stimulated activation of both mutants is significantly reduced (Fig. 10A ). This effect is more pronounced for the Y284C mutant. Both Y284F (Fig. 10B ) and Y284C mutants, as well as the S217G mutant, can be rescued by the pharmacoperone In3 and/or deletion of Lys 191 (Fig. 10 , A and B) (Knollman et al., 2005) . After pretreatment with In3, the S217G mutant demonstrates buserelin-stimulated activation similar to the WT receptor, whereas Y284F and Y284C show 70 and 23% activity, respectively. These results indicate that the effect of the reduced receptor activation by agonist is partially attributed to the impaired trafficking of the mutants.
The larger impairment of the Y284C suggests the importance of both the OH-group and the aromatic ring of Tyr 284 for proper receptor trafficking and activation. However, the difference between both Tyr 284 mutants may also be related to different binding affinities of these mutants to drugs and peptide ligands. To examine this possibility, we analyzed dose-response curves of these mutants with buserelin, as well as the inhibition of buserelin-induced activity by the highaffinity peptide antagonist acyline (Fig. 10C) . These experiments show that the binding affinities of all mutants to peptide agonist buserelin and antagonist acyline were similar to the corresponding affinities of the WT receptor. Considering these results together with the reduced CA of the E90K/S217G double mutant, we conclude that a) the aromatic ring and OH-group of the Tyr 284 are essential for receptor activation; and b) the formation of the H-bond between Ser 217 and Tyr 284 or other polar groups is probably involved in the activation process.
Discussion
Transmembrane proteins expressed in ER, such as GPCRs, are subject to a QCS that assesses receptor structure, retaining some mutants in the ER and promoting the exit from the ER of others (Achour et al., 2008) . Correctly folded GPCRs pass the QCS and traffic via the Golgi complex to the PM or other cellular locus where they function appropriately. The QCS is not protein-specific; it recognizes general aspects of Fig. 9 . IP production by WT GnRHR and various mutants expressed in COS-7 cells in response to 10 Ϫ9 M agonist (buserelin) and in the presence of Q89. A, human: COS-7 cells were transiently transfected with 10 ng of human WT or human mutant cDNA plus 90 ng of empty vector, and IP production was determined as described under Materials and Methods. B, rat: COS-7 cells were transiently transfected with 5 ng of rat WT or rat mutant cDNA plus 95 ng of empty vector, and IP production was determined as described under Materials and Methods. Means Ϯ S.E.M.s are shown for three independent experiments, each performed in replicates of four.
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at ASPET Journals on July 13, 2017 jpet.aspetjournals.org Downloaded from misfolding (e.g., exposure of hydrophobic plates in aqueous environments or unformed Cys bridges), often with relatively low affinity. Accordingly, GPCRs or their mutants that are potentially functional but not completely folded may be retained and destined for degradation. As shown in the present report, the requirements for passage through the QCS and for receptor activation may differ. Pharmacoperones are target-specific, low molecular weight structures that enter cells and bind to otherwise misfolded proteins, correct their folding , and promote passage through the QCS and arrival at the correct functional location. The functional rescue of several misfolded mutant proteins by small nonpeptide molecules has been demonstrated .
In the present study, structural models for the hGnRHR in active and inactive conformations were developed and tested. These models feature two salt bridges (Glu 90 (Zhou et al., 1995; Flanagan et al., 2000) . Accordingly, the binding of GnRH will disrupt both ionic interactions simultaneously, thus presenting the possibility of a coincidence detector. Coincidence mechanisms encode information by detecting the occurrence of simultaneous yet distinct input signals. Detection by coincidence is well known to reduce spurious signals in biological systems and could explain, in the present context, why antagonists do not produce a response. Failure to activate this detector may explain the function of antagonists, which may not interact with Lys 121 (Zhou et al., 1995) . This is consistent with the observation that mutants that totally break the Glu 90 -Lys 121 bridge (i.e., E90K) show CA (Janovick and Conn, 2010) . In contrast, mutations that break the Arg 38 -Asp 98 bridge do not cause CA but weaken receptor stability (poor trafficking) and impair ligand binding, given that both residues form key contacts with natural ligands. The level of CA for the E90K mutant is modest: the receptor does not produce the same robust response that is observed with agonist occupancy, suggesting that the structure of the receptor is nonidentical with the change in the receptor that occurs when an agonist binds.
Our modeling suggests that CA is probably associated with relative movement of helices accompanied by the rearrangement of the hydrogen bonding network between TMs 1, 2, 3, 6, and 7 and the formation of a tight connection between TM2 and TM7 that may be stabilized by ionic interactions between E90K and Asp 319 . With the deletion of Lys 191 and L112F, Q208E, L300V, and D302E substitutions, the CA of the E90K mutant substantially increases. In this case, the activation process may additionally involve movement of EL2 relative to noncontiguous residues from surrounding helices and loops, as was suggested based on computational modeling of agonist-bound active conformation.
The importance of the region of the GnRHR molecule with these two salt bridges is emphasized by the observation that a ligand (Asp 2 -GnRH) that was not recognized by WT hGnRHR becomes an agonist for E90K once this molecule is rescued and trafficked to the plasma membrane (Janovick and Conn, 2010) . The computational models suggest that, in the active conformation of the E90K mutant, the side chain of Lys A, mutants were rescued with pharmacoperone (In3) as described under Materials and Methods; In3 was then washed out, and IP production was measured in response to the indicated dose of buserelin. B, WT GnRHR or mutants were incubated in media alone or rescued with pharmacoperone In3 as described under Materials and Methods; In3 was then washed out, and IP production was measured in response to medium alone or agonist (10 Ϫ7 M buserelin). C, mutants were rescued with pharmacoperone (In3) as described under Materials and Methods; In3 was then washed out, and IP production was measured in response to antagonist (acyline) dose-response curve containing agonist (10 Ϫ9 M buserelin). In all figures, Means Ϯ S.E.M.s are shown for three independent experiments, each performed in replicates of four.
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